Compare ConocoPhillips (COP) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs GSK plc — how do they compare? ConocoPhillips trades at $134.1 (market cap $161.21B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: ConocoPhillips is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and GSK plc for 93 Days on average.
| COP | GSK | |
|---|---|---|
Market Cap | $161.21B | $91.88B |
Volume | 6,058,403 | 7,730,529 |
Sector | Energy | Health |
52-Week High | $141.22 | $61.18 |
52-Week Low | $85.66 | $43.24 |
Typical Hold Time | 79 Days | 93 Days |
Enterprise Value | $176.81B | $111.88B |
Dividend Yield | 2.5% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $134.19, up 3.35% with strong technical momentum. The stock shows robust fundamentals with a P/E of 17.75, net income margin of 14.65%, and consistent earnings beats in recent quarters. Recent developments include a 20-year LNG supply agreement with Venture Global and potential asset sales in Norway and the UK. Technical indicators show bullish moving averages with the stock trading near pivot point resistance at $134.
COP presents a compelling investment case with strong analyst support (75% buy rating) and a $154.75 price target offering 15% upside. However, investors face risks from oil price volatility, geopolitical tensions affecting international operations, and declining profit margins from 23.79% in 2022 to 13.55% in 2025. The company's solid cash flow generation and strategic LNG expansion provide growth catalysts.
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
